Blood test could detect hidden pancreatic tumors

NCT ID NCT05847855

First seen Jun 24, 2026 · Last updated Jun 24, 2026

Summary

This study is testing a new blood test that looks at fragments of DNA to find pancreatic neuroendocrine tumors early and tell them apart from other pancreatic tumors. Researchers will collect blood from 1,000 adults with different types of pancreatic tumors to see how accurate the test is. If it works, it could lead to earlier detection and better treatment decisions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University shanghai cancer center

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

    Contact

    Contact Phone: •••-•••-••••

    Contact

  • West China Hospital, Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this blood test could help doctors find pancreatic neuroendocrine tumors earlier and avoid unnecessary surgeries by distinguishing tumor types.

What could go wrong

This is an early diagnostic study, not a treatment. The test may not be accurate enough in real-world settings, and results may not apply to all patients.

Conditions

The condition(s) this trial relates to.

Adenoma, Islet Cell pancreatic ductal adenocarcinoma pancreatic neoplasm pancreatic neuroendocrine tumor solid pseudopapillary neoplasm of the pancreas

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.